Poster Spotlight Session: Less is More.

Dr Tari A. King, MD moderates a poster session focused on "Minimizing Surgical Treatment in Patients with Early Stage Breast Cancer" and discussions by Melissa Pilewskie, MD, FACS and
(PS01-01) Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prospective MF-1803 NEOSENTITURK-study: Neslihan Cabıoğlu
(PS01-02) Long-term outcomes of sentinel lymph node biopsy following neoadjuvant chemotherapy for initially node-positive breast cancer: A systematic review and meta-analysis. Mariam Rana, BSc MBBS FRCSC
(PS01-03) What to expect from the No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS] trial (KBCSG-21): Clinicopathologic characteristics and axillary lymph node status of enrolled patients: Jai Min Ryu, MD, PhD
(PS01-04) To dissect or not to dissect? The surgeon’s perspective on the prediction of ≥ 4 axillary lymph node metastasis in cN0 T1-2 breast cancer: A comparative analysis of the per-protocol population of the SINODAR-ONE clinical trial. Damiano Gentile
(PS01-06) The relationship between margin status of 2mm and local recurrence in DCIS patients: Sarah Alsafi, MD
(PS01-07) Impact of Race and Ethnicity on Recurrence Risk in Patients with Ductal Carcinoma in Situ Treated with Breast-Conserving Surgery: Natalia Polidorio, MD, PhD
(PS01-08) Management of ipsilateral breast tumor recurrence following breast conservation surgery for ductal carcinoma in situ – a data-free zone: Brian Diskin, MD
(PS01-09) Early Results of a Phase I Pre-Operative Single Fraction Ablative Trial for Early Stage Breast Cancer: Asal Rahimi, MD, MS
(PS01-10) Surgical margins in breast conserving surgery (BCS) for ductal carcinoma in-situ (DCIS) and clinical outcomes: significant associations with increased recurrence and overall survival. D Mark Sibbering, FRCS